



- (51) **International Patent Classification:**
C12P 21/04 (2006.01) *A61K 9/127* (2006.01)
C12N 5/00 (2006.01)
- (21) **International Application Number:**
PCT/US2014/071388
- (22) **International Filing Date:**
19 December 2014 (19.12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/918,833 20 December 2013 (20.12.2013) US
- (71) **Applicant:** **ESSENTIAL PHARMACEUTICALS, LLC**
[US/US]; 100 Princeton South Corporate Center, 1st Floor,
Suite 140, Ewing, NJ 08628 (US).
- (72) **Inventors:** **ELHOFY, Adam**; 100 Princeton South Cor-
porate Center, 1st Floor, Suite 140, Ewing, NJ 08628 (US).
WEBER, Allan; 100 Princeton South Corporate Center,
1st Floor, Suite 140, Ewing, NJ 08628 (US).
- (74) **Agent:** **NEVILLE, Katherine, L.**; Marshall, Gerstein &
Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower,
Chicago, IL 60606-6357 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** MEDIA FOR CELL CULTURE

(57) **Abstract:** The present disclosure relates, in general, to a media, e.g., a serum replacement, media supplement, complete media or cryopreservation media, comprising a base physiological buffer and liposomes comprising cholesterol, phosphatidylcholine and fatty acids. It is contemplated that media provides advantages to improve cell growth in culture compared to cells cultured not using the serum replacement described herein.

